Claims for Patent: 6,100,444

Summary for Patent: 6,100,444

Title:	Prostate specific regulatory nucleic acid sequences and transgenic non-human animals expressing prostate specific antigen
Abstract:	The non-coding regulatory sequences of the prostate specific antigen (PSA) are described. Non-human transgenic animals are also provided which express human PSA, which is non-naturally occurring in non-human animals.
Inventor(s):	Frelinger; John G. (Pittsford, NY), Barth; Richard K. (Rochester, NY), Wei; Chungwen (Pittsford, NY)
Assignee:	University of Rochester Medical Center (Rochester, NY)
Application Number:	08/797,722
Patent Claims:	1. An isolated nucleic acid sequence comprising a 5' non-coding regulatory sequence about 6 kb in length of human prostate specific antigen gene and a 3' non-coding regulatory sequence of human prostate specific antigen gene. 2. The nucleic acid sequence of claim 1, wherein said 3' non-coding regulatory sequence comprises a sequence about 2 kb in length. 3. The nucleic acid sequence of claim 1, further comprising an intron of human prostate specific antigen gene. 4. A nucleic acid construct, comprising a heterologous nucleic acid sequence operatively linked to the nucleic acid sequence of claim 1. 5. The nucleic acid construct of claim 4, further comprising a transcriptional and translational initiation region and a transcriptional termination region functional in an animal cell. 6. The nucleic acid construct of claim 4, wherein the heterologous nucleic acid sequence encodes an agent selected from the group consisting of an immunomodulator, a biological response modifier, an antisense nucleic acid, and a ribozyme. 7. The nucleic acid construct of claim 4, wherein the heterologous nucleic acid sequence encodes a biologically active protein. 8. The nucleic acid construct of claim 4, wherein the heterologous nucleic acid sequence contains an antisense RNA for regulating expression of an endogenous coding sequence. 9. An isolated prostate cell or coagulating gland/seminal vesicle cell, wherein said cell is isolated from a transgenic mouse comprising a nucleic acid construct according to claim 4. 10. A non-human transformed cell comprising the nucleic acid construct of claim 4, wherein said cell expresses said heterologous sequence. 11. An isolated transformed cell comprising the nucleic acid construct of claim 4, wherein said cell expresses said heterologous sequence. 12. A transgenic mouse, comprising a nucleic acid construct according to claim 4, wherein the heterologous nucleic acid sequence is expressed in prostate tissue at detectable levels. 13. A transgenic mouse that expresses human prostate specific antigen in prostate tissue, said human prostate specific antigen otherwise not naturally occurring in said mouse, said expression being conferred by a transgene contained in the somatic and germ cells of said mouse, said transgene comprising a nucleic acid sequence which encodes a human prostate specific antigen polypeptide operably linked to a human prostate specific antigen non-coding regulatory sequence, wherein said expression of human prostate specific antigen in said prostate tissue is at detectable levels in said mouse. 14. A method for producing a transgenic mouse that expresses detectable levels of human prostate specific antigen in prostate tissue, human prostate specific antigen otherwise not naturally occurring in said mouse, said method comprising: a) introducing a transgene into an embryo of a mouse, said transgene comprising a DNA construct encoding a human prostate specific antigen operably linked to a human prostate specific antigen non-coding regulatory sequence, b) transplanting said embryo into a pseudopregnant animal, c) allowing said embryo to develop to term, and d) identifying at least one transgenic offspring containing said transgene that expresses human prostate specific antigen at detectable levels in prostate tissue. 15. The method of claim 14, wherein said introducing of said transgene into said embryo is by introducing an embryonic stem cell containing said transgene into said embryo. 16. The method of claim 14, wherein said introducing of said transgene into said embryo is by infecting said embryo with a retrovirus containing said transgene.

Details for Patent 6,100,444

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26